Maggie L. Shaw

Patient survival and such treatment-related outcomes as time to treatment failure and treatment duration improved following implementation of a best practices program that focused on selinexor administration for multiple myeloma (MM), with implications for other anticancer medications.

Serena Sloane, a Pittsburgh-based certified nursing assistant, took advantage of a chance meeting at her laundromat with someone from Fabric Health to learn more about her options for bettering her health care benefits

MEDLINE, the Turning Research Into Practice database, Google Scholar, and organization guidelines were searched for their ongoing applicability to the management of Duchenne muscular dystrophy (DMD) and to determine if there is a need to develop new treatment recommendations.

The TROP-2–directed antibody drug conjugate is currently being investigated as a monotherapy and a combination therapy for non–small cell lung cancer (NSCLC) in 3 trials: phase 3 EVOKE-01, phase 2 EVOKE-02, and phase 3 EVOKE-03.

This new economic valuation of the societal and health care benefits of gene therapy to treat sickle cell disease (SCD) concludes the highly personalized treatment has potential to be cost effective if priced below $2 million.

Registered dietitian, Molly Kimball, RD, CSSD, of Ochsner Health, navigates cultural identity in diet changes for long-term success, in an interview.

This literature review investigated outcomes related to relapsed/refractory multiple myeloma (MM) among patients 65 years and older.

Molly Kimball, RD, CSSD, of Ochsner Health, advocates for sustainable changes to populations' everyday behaviors to make healthy choices easier and more culturally relevant.

Myelodysplastic syndrome is an extremely heterogeneous disease, and there is no definitive cure, so these investigators wanted a better understanding of patients’ priorities regarding their care, quality of life, and communication with the care team.

This new study examined postoperative survival among discharged patients following treatment of non–small cell lung cancer (NSCLC) via surgical resection using the National Cancer Database.

Patient-reported outcomes data regarding measures of health-related quality of life, also known as health state utilities, in Duchenne muscular dystrophy (DMD) are scarce, with current knowledge in this area concentrated in caregiver feedback.

Sidney (Beau) Raymond, MD, MMM, FACP, chief medical officer of Ochsner Health Network, believes that the health care system should focus on preventing illness and disease, rather than just treating them after they occur.

Amrish Selvam is a fourth-year medical student at the University of Pittsburgh whose research and career interests lay in ophthalmology and who volunteers with the UPMC Vision Institute’s mobile eye clinic, the eyeVan.

A social-impact startup, Pittsburgh-based Fabric Health is adept at using community engagement to help members and their families navigate the complex world of health care—meeting customers where they are at, knowing time is often their most valuable resource.

Delandistrogene moxeparvovec-rokl (Elevidys; Sarepta Therapeutics) is currently approved to treat Duchenne muscular dystrophy in 4- and 5-year-old patients who have a confirmed DMD gene mutation.

In this interview with Katie Cecconi, community service program coordinator at the UPMC Vision Institute, we learn more about the institute’s mobile eye care initiatives and how its services are working to overcome care equity gaps.

A qualitative interview study gauged patients’ experiences with belantamab mafodotin, which is used to treat relapsed/refractory multiple myeloma (RRMM) following failure on at least 4 prior therapies.

Outcomes between 2 patients groups affected by uncontrolled type 2 diabetes and food insecurity were compared for change in hemoglobin A1C after 1 year of participation.

A multidisciplinary team has proposed respiratory care guidance for pediatric and adult patients living with Duchenne muscular dystrophy (DMD) in the United Kingdom (UK), with these recommendations meant to optimize DMD care day to day and in acute episodes.

This year’s top content from the annual San Antonino Breast Cancer Symposium (SABCS) is concentrated in 3 areas: health equity, benign breast disease, and fertility preservation following diagnosis.

Following implementation of low-dose rituximab as standard of care for muscle-specific kinase–positive myasthenia gravis (MuSK-MG), a hospital evaluated the treatment’s efficacy over a 2-year period.

While the Enhancing Oncology Model is the successor of the Oncology Care Model, it includes some very real challenges for participating practices, explained Lalan Wilfong, MD, senior vice president of payer and care transformation at The US Oncology Network.

In breast cancer coverage this year, topline results from the phase 3 NATALEE trial made waves in March, with our other most-read content in the space covering an expanded indication for abemaciclib, revised screening recommendations, a new potential treatment to reduce radiation exposure, and the benefits of diet and exercise on patient outcomes.

In September, The American Journal of Managed Care® joined 4 individuals whose involvement with UPMC Health Plan, a Strategic Alliance Partner of AJMC®, has proved to be instrumental in furthering health equity and providing high-quality care in Pennsylvania, Ohio, West Virginia, and Maryland.

At this year’s Community Oncology Alliance Payer Exchange Summit on Oncology Payment Reform, leaders from across all facets of the cancer care space engaged in thought-provoking panel discussions and debates. They have a common aim: to optimize cancer care delivery and ensure patients have a positive experience throughout their cancer care journey.

A one-size-fits-all approach to alternative payment models (APMs) often isn’t very fair to community practices, said Miriam Atkins, MD, FACP, president of the Community Oncology Alliance.

This year’s top content in the Duchenne muscular dystrophy (DMD) space focused on a novel gene therapy approval, the high cost of care for this genetic disorder, and steps forward in other treatments.

Join Shiela Plasencia, director of practice support, Community Oncology Alliance (COA) as she explores improving health treatments for marginalized communities and how to apply it to the oncology population.

Peter Katzmarzyk discusses contributing factors to obesity and the chronic disease preventions and implementations collaborative care teams like nutritionists, psychologists, and physical therapists should support.